Baird Financial Group, Inc. Eye Point Pharmaceuticals, Inc. Transaction History
Baird Financial Group, Inc.
- $59 Billion
- Q3 2025
A detailed history of Baird Financial Group, Inc. transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Baird Financial Group, Inc. holds 17,518 shares of EYPT stock, worth $207,588. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,518Holding current value
$207,588% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding EYPT
# of Institutions
167Shares Held
68.8MCall Options Held
421KPut Options Held
401K-
Cormorant Asset Management, LP Boston, MA8.33MShares$98.7 Million18.35% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.19MShares$73.4 Million2.57% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.56MShares$65.9 Million0.13% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.42MShares$52.3 Million0.12% of portfolio
-
Franklin Resources Inc San Mateo, CA4.17MShares$49.4 Million0.02% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $404M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...